Trial reportBMC clinical pharmacology2009
Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: part B - behavioral results.
Trial report in BMC clinical pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Environmental toxicants and autism spectrum disorders: a systematic review.Translational psychiatry · 2014Pooled it
- Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders: Part A--medical results.BMC clinical pharmacology · 2009Trial
- Perinatal Exposure to Trace Elements: The Dubious Culprit of Autistic Spectrum Disorder in Children.Current pediatric reviews · 2024Review
- Significant Association of Urinary Toxic Metals and Autism-Related Symptoms-A Nonlinear Statistical Analysis with Cross Validation.PloS one · 2017Article
- Chelation for autism spectrum disorder (ASD).The Cochrane database of systematic reviews · 2015Article
- Toxicant exposure and bioaccumulation: a common and potentially reversible cause of cognitive dysfunction and dementia.Behavioural neurology · 2015Article
- Proposed toxic and hypoxic impairment of a brainstem locus in autism.International journal of environmental research and public health · 2013Article
- The role of nutraceuticals in the management of autism.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2013Review
- Chelation: harnessing and enhancing heavy metal detoxification--a review.TheScientificWorldJournal · 2013Review
- Efficacy of DMSA Therapy in a Sample of Arab Children with Autistic Spectrum Disorder.Maedica · 2012Article
- A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures.Molecular psychiatry · 2012Review
- A review of complementary and alternative treatments for autism spectrum disorders.Autism research and treatment · 2012Article
- Environmental determinants of chronic disease and medical approaches: recognition, avoidance, supportive therapy, and detoxification.Journal of environmental and public health · 2012Review
- Is dental amalgam safe for humans? The opinion of the scientific committee of the European Commission.Journal of occupational medicine and toxicology (London, England) · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the effects of oral dimercapto succinic acid (DMSA) therapy on the behavioural symptoms of children with autism spectrum disorders (ASD) ages 3-8 years.
methodsPhase 1 involved 65 children with ASD who received one round of DMSA (3 days). Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2. In phase 2, 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo.
resultsThe groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures. For the seven round group, the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione (adjusted R2 of 0.28-0.75, p < 0.02 in all cases). One round of DMSA had nearly the same benefit as seven rounds. The assessment measures correlated reasonably with one another at the beginning of the study (r = 0.60-0.87) and even better at the end of the study (r = 0.63-0.94).
conclusionOverall, both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals, and possibly helpful in reducing some of the symptoms of autism in those children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.